KERLONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kerlone, and when can generic versions of Kerlone launch?
Kerlone is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in KERLONE is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kerlone
A generic version of KERLONE was approved as betaxolol hydrochloride by EPIC PHARMA on October 22nd, 1999.
Summary for KERLONE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 212 |
Clinical Trials: | 1 |
Patent Applications: | 4,076 |
Formulation / Manufacturing: | see details |
DailyMed Link: | KERLONE at DailyMed |
Recent Clinical Trials for KERLONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Centre Hospitalier Universitaire de Saint Etienne | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for KERLONE
US Patents and Regulatory Information for KERLONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | KERLONE | betaxolol hydrochloride | TABLET;ORAL | 019507-001 | Oct 27, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | KERLONE | betaxolol hydrochloride | TABLET;ORAL | 019507-002 | Oct 27, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |